De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review

Background: The long-term use of anti-TNF-α agents can lead to adverse effects, such as infections and immune-mediated cutaneous reactions. Whether de-escalation by dose reduction or interval lengthening reduces these adverse effects is uncertain. This systematic review aims to compare the incidence...

Full description

Bibliographic Details
Main Authors:	Marleen Bouhuys, Willem S. Lexmond, Patrick F. van Rheenen
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Biomedicines
Subjects:	tumor necrosis factor inhibitors infliximab adalimumab etanercept golimumab certolizumab pegol
Online Access:	https://www.mdpi.com/2227-9059/10/5/1034

Similar Items

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases
by: Loris Riccardo Lopetuso, et al.
Published: (2023-05-01)

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
by: E. V. Voronina, et al.
Published: (2018-12-01)

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
by: Matt Stevenson, et al.
Published: (2016-04-01)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
by: Megumi Kishimoto, et al.
Published: (2023-05-01)

Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study
by: Pedersen L, et al.
Published: (2020-10-01)

Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population
by: Mark Bounthavong, et al.
Published: (2014-05-01)

Severe psoriatic arthritis in an HIV/AIDS patient treated with several TNF blockers switching: a case-based review
by: J. Carvalho, et al.
Published: (2022-01-01)

Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
by: Irina A Tikhonova, et al.
Published: (2021-02-01)

Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis
by: Boris Gole, et al.
Published: (2019-05-01)

Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study
by: Soo Min Ahn, et al.
Published: (2022-01-01)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
by: Cristiano Pagnini, et al.
Published: (2021-09-01)

Incidencia de tuberculosis en pacientes que reciben fármacos anti-TNFα
by: Ana Gruss, et al.
Published: (2020-03-01)

Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison
by: Yehua Wang, et al.
Published: (2016-09-01)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
by: Teppei Hagino, et al.
Published: (2023-01-01)

Golimumab Therapy in Ulcerative Colitis
by: Won Moon
Published: (2016-02-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis
by: Szilárd Póliska, et al.
Published: (2019-04-01)

New Treatment Alternatives in the Management of Non-‹nfectious ‹ntraocular ‹nflammations: Biologic Agents
by: Sinan Emre, et al.
Published: (2011-08-01)

TNF-alpha blockers in inflammatory bowel diseases: Practical consensus recommendations and a user's guide
by: C Felley
Published: (2009-05-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
by: Yael Sharon, et al.
Published: (2020-06-01)

Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis
by: Atsushi Yoshida, et al.
Published: (2021-04-01)

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS
by: Dmitry Evgenyevich Karateyev
Published: (2009-09-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα Immediate complications of 3,555 injections of anti-TNFα
by: Júlio César Bertacini de Moraes, et al.
Published: (2010-04-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
by: Maria Majdan, et al.
Published: (2014-07-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
by: Vivian P. Bykerk, et al.
Published: (2023-02-01)

Targeting psoriasis with new therapies
by: A.Prohić;H. Helppikangas;J. Muhović
Published: (2007-08-01)

UTILIZAÇÃO OFF-LABEL DE TERAPÊUTICA BIOLÓGICA EM DERMATOLOGIA – EXPERIÊNCIA CLÍNICA DE 5 ANOS
by: Filipa Diamantino, et al.
Published: (2016-11-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
by: Júlio César Bertacini de Moraes, et al.

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01)

Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study
by: Giannis Chatzimichail, et al.
Published: (2022-04-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I.L. Khalif, et al.
Published: (2018-04-01)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
by: A. Spadaro, et al.
Published: (2013-07-01)

THERAPEUTIC APPROACH OF A CASE OF RHEUMATOID ARTHRITIS COMPLICATED WITH RENAL AMYLOIDOSIS IN A YOUNG WOMAN
by: Alexandra Burlui, et al.
Published: (2017-03-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I L Khalif, et al.
Published: (2018-04-01)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
by: Cristina Membrive-Jiménez, et al.
Published: (2023-05-01)

Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: A systematic review
by: Rana Majdi Abunemer, et al.
Published: (2023-11-01)

Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review
by: Vidhi V. Shah, et al.
Published: (2018-08-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

Switching Among Biosimilars: A Review of Clinical Evidence
by: Eleonora Allocati, et al.
Published: (2022-08-01)